{"id":390755,"date":"2017-12-24T00:00:00","date_gmt":"2017-12-24T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0002-2017-biopharma-asthma-access-and-reimbursement-us-2017\/"},"modified":"2026-03-31T10:49:00","modified_gmt":"2026-03-31T10:49:00","slug":"acreim0002-2017-biopharma-asthma-access-and-reimbursement-us-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0002-2017-biopharma-asthma-access-and-reimbursement-us-2017\/","title":{"rendered":"Asthma | Access and Reimbursement | US | 2017"},"content":{"rendered":"<p><strong>Market Outlook<\/strong><\/p>\n<p>The dynamics within the LABA\/ICS FDC,\u00a0<abbr title=\"long-acting muscarinic antagonist\">LAMA<\/abbr>, and biological drug classes will continue to shape the U.S. asthma market. The dominance of branded LABA\/ICS FDCs\u00a0(e.g., GSK\u2019s\u00a0Advair, AstraZeneca\u2019s\u00a0Symbicort) will be called into question, as new generic\/branded-generic agents continue to launch over the next several years. In addition, the market entrance of LABA\/LAMA\/ICS FDCs\u00a0could create uptake challenges for Boehringer Ingelheim\u2019s\u00a0Spiriva\u2014which, despite notable previous off-label use, was only recently approved for asthma. Finally, the launch of novel biologics will fuel increasing competition and pricing pressure in the severe, refractory segment of the asthma market. Overall, with the impending entry of multiple new branded and generic therapies, marketers of current\u2014and emerging\u2014asthma agents will be faced with increasing challenges to gain favorable formulary position and market uptake.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>Which key asthma therapies (e.g., Advair, Symbicort, GSK\u2019s Breo, Novartis\u2019s Xolair, GSK\u2019s Nucala, Teva\u2019s Cinqair) receive favorable formulary placement, and what approaches do payers employ to manage utilization and costs?<\/li>\n<li>How do reimbursement restrictions impact physicians\u2019 prescribing of LABA\/ICS FDCs, Spiriva, and biologics to their asthma patients?<\/li>\n<li>How do payers expect current and emerging generic\/branded-generic versions of market-leading LABA\/ICS FDCs\u00a0(e.g., Teva\u2019s AirDuo RespiClick\/authorized generic,\u00a0<abbr title=\"FDA-approved as substitutable\">AB-rated<\/abbr>\u00a0generics of Advair and Symbicort) will impact access to branded therapies? How do physicians expect to prescribe these generics\/branded-generic alternatives?<\/li>\n<li>How do physicians anticipate using select emerging biologics (i.e., AstraZeneca\u2019s Fasenra [benralizumab], Sanofi\/Regeneron\u2019s Dupixent [dupilumab]) and LABA\/LAMA\/ICS FDCs\u00a0(i.e., GSK\u2019s Trelegy [vilanterol\/umeclidinium\/fluticasone furoate]), and how do payers expect to cover these therapies on commercial health plans at various price points?<\/li>\n<\/ul>\n<p><strong>Product\u00a0\u00a0Description<\/strong><\/p>\n<p>Access &#038; Reimbursement: Provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.<\/p>\n","protected":false},"template":"","class_list":["post-390755","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-asthma","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390755","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390755\/revisions"}],"predecessor-version":[{"id":576759,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390755\/revisions\/576759"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390755"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}